- Nurix Therapeutics reported third quarter revenue of US$673.06 million and net income of US$549.81 million, compared with much smaller revenue and a net loss in the same period last year, with basic earnings per share from continuing operations at US$4.93.
- The business has moved from a net loss of US$186.24 million over the first nine months of last year to net income of US$373.1 million this year, indicating a major shift in Nurix Therapeutics' operating profile and cost or partnership economics.
- This sharp swing to profitability and several hundred million dollars in revenue is likely to be an important factor in how investors assess Nurix Therapeutics' investment narrative.
What Is Nurix Therapeutics' Investment Narrative?
To own Nurix Therapeutics, you need to believe the current profitability is more than a one off and that its drug discovery engine and partnerships can keep generating economic value. The third quarter swing to US$549.81 million of net income on US$673.06 million of revenue, plus US$373.1 million of profit over nine months, points to meaningful execution on deals and cost control. The NX-5948 clinical momentum with Roche and the extended collaboration with Gilead suggest that, in the near term, program progress and partner decisions matter more than broad biotech sentiment.
In the short term, the key catalysts now sit in trial readouts for bexobrutideg, how the Gilead alliance converts into milestones, and whether this earnings surge recurs or normalizes. The risk side is real. Forecasts point to declining revenue and earnings over the next three years, and shareholders have already absorbed substantial dilution, so operational success has to offset those pressures for the Nurix Therapeutics story to keep working.
That said, set against the profitability headlines and clinical updates, one structural risk still hangs over Nurix Therapeutics and could easily reshape the upside case if ...
There's only one way to know the right time to buy, sell or hold Nurix Therapeutics. Head to Simply Wall St's company report for the latest analysis of Nurix Therapeutics's Fair Value.
Exploring Other Perspectives
Some of the most optimistic analysts frame the Roche bexobrutideg program as the real swing factor for Nurix Therapeutics. Before this earnings surprise, they were pencilling in revenue of about US$640.4 million and earnings of US$240.4 million by 2029, which is far above the more cautious camp. Use this quarter to test which story you think might gain traction next.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Nurix Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Nurix Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Nurix Therapeutics?
Once you have formed a view on Nurix Therapeutics, it can help to put that thesis alongside other businesses with very different risk and reward profiles. The Simply Wall St Screener lets you scan for stocks that match the type of setup you are hunting for, rather than working through tickers one by one.
- If you want potential mispricing at the quality end of the market, start with a curated group of 32 high quality undervalued stocks that combine fundamentals and pricing you can interrogate in seconds.
- For investors who care most about resilience, sort through a 32 resilient stocks with low risk scores and see which companies line up with your tolerance for volatility and balance sheet strength.
- If you prefer businesses with cleaner finances, filter for a list of solid balance sheet and fundamentals (25 results) and compare which ones best complement your view on Nurix Therapeutics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com